Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD

Bone Marrow Transplantation volume 42, pages 541–546 (2008)Cite this article

Abstract

Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD after allogeneic hematopoietic SCT for hematological malignancies were evaluated for response. Five patients had isolated gastrointestinal cGVHD and 8 patients had mild multiorgan involvement including gastrointestinal manifestations. Six patients received CYA at the time of onset of cGVHD, which was continued during treatment with BUD. Treatment consisted of BUD, with an initial daily dose of 3 × 3 mg orally. Complete resolution of cGVHD was achieved in seven patients, and one patient achieved partial remission of cGVHD. One patient achieved complete resolution of gastrointestinal cGVHD, while systemic manifestations of cGVHD remained stable. Four patients progressed on BUD. Owing to the predominantly local effect, relapse of symptoms of cGVHD after withdrawal of immunosuppression (n=3) as well as progression of GVHD at other sites (n=3) has been observed. BUD represents a treatment option in mild-to-moderate cGVHD, which is well tolerated and associated with a high response rate in gastrointestinal cGVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  2. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB . Weight loss and malnutrition in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 231–236.

    Article  CAS  PubMed  Google Scholar 

  3. Patey-Mariaud dS, Reijasse D, Verkarre V, Canioni D, Colomb V, Haddad E et al. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant 2002; 29: 223–230.

    Article  Google Scholar 

  4. Sale GE, Shulman HM, McDonald GB, Thomas ED . Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol 1979; 3: 291–299.

    Article  CAS  PubMed  Google Scholar 

  5. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  6. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S, McGlave P . A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 1985; 16: 387–392.

    Article  CAS  PubMed  Google Scholar 

  7. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease—II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12: 31–47.

    Article  PubMed  Google Scholar 

  8. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061–1067.

    CAS  PubMed  Google Scholar 

  9. Wolff D, Anders V, Corio R, Horn T, Morison WL, Farmer E et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs-host disease. Photodermatol Photoimmunol Photomed 2004; 20: 184–190.

    Article  CAS  PubMed  Google Scholar 

  10. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J . Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999; 24: 1185–1189.

    Article  CAS  PubMed  Google Scholar 

  11. Elad S, Or R, Garfunkel AA, Shapira MY . Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 308–311.

    Article  PubMed  Google Scholar 

  12. McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115: 28–35.

    Article  CAS  PubMed  Google Scholar 

  13. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557–4563.

    Article  CAS  PubMed  Google Scholar 

  14. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731.

    Article  CAS  PubMed  Google Scholar 

  15. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008; 41: 721–727.

    Article  CAS  PubMed  Google Scholar 

  16. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003–1010.

    Article  CAS  PubMed  Google Scholar 

  17. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  18. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100: 48–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Rostock, Rostock, Germany

    H Andree, I Hilgendorf, M Leithaeuser, C Junghanss, B Steiner, M Freund & D Wolff

  2. Department of Pathology, University of Rostock, Rostock, Germany

    S Holzhueter

  3. Department of Pathology, Campus Benjamin Franklin, Charité—University Hospital Berlin, Berlin, Germany

    C Loddenkemper

Authors
  1. H Andree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Hilgendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Leithaeuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Junghanss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Holzhueter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Loddenkemper
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Wolff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andree, H., Hilgendorf, I., Leithaeuser, M. et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transplant 42, 541–546 (2008). https://doi.org/10.1038/bmt.2008.209

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.209

Keywords

This article is cited by

Search

Advanced search

Quick links